Biocon Ltd

NSE : BIOCON

BSE: 532523

SECTOR : PHARMACEUTICALS

No data to show from BSE

52w high/low	₹474.35 / ₹314.8
P/E ratio	17.17
Dividend	0.55
ROE	0.55
ROCE	1.89
Face value	5
Book value	₹90.38Cr
Market capital	₹32,902.44Cr

Shareholding pattern

What is shareholding pattern? Who are shareholders?

Shareholding pattern represents the percentage of share ownership that different investors are holding in the company. A company can have multiple investors who invest in its shares. These are called as shareholders and there are two major categories of shareholders - promoters and public shareholders.

Promoters are typically the founders and public shareholders could be financial institutes like banks, insurance companies, domestic institutional investors, foreign institutional investors and common public.

Cash flow

What is a cash flow statement?

It is a financial statement that offers aggregate statistics on all cash inflows a business collects from its continuing activities and external sources of investment. It also includes all cash outflows over a specified time paying for company operations and investments.The main components of the CFS are cash from three areas: operating, investing, and financing activities...Read more

Balance Sheet

What is a balance sheet?

A balance sheet is a financial statement that records the assets, liabilities, and equity of a company at a certain point in time and provides a basis for estimating return rates and determining the capital structure. It offers a snapshot of what an entity owns and owes, as well as the sum that shareholders spend.The balance sheet complies with the following accounting equation in which assets on the one side, and liabilities plus shareholders' equity on the other, balance out:

Assets = Liabilities + Shareholder's Equity

This is used to conduct fundamental analysis or the estimation of financial ratios alongside other essential financial statements, such as income statement and statement of cash flows...Read more

Profit and loss

What is a profit and loss statement?

A profit and loss statement is a financial statement that represents the revenues, costs and expenses that the company has incurred during a quater or a fiscal year. It is also sometimes referred to as statement of profit and loss, income statement or statement of operations. This statement basically shows the investors and management whether the company has incurred profits or losses and in which areas.

Key Ratios

PE TTM

17.17

P/B

3.03

ROE

0.55

ROCE

1.89

Dividend yield

0.55%

EPS TTM

0.4

EBTIDA Growth

1171.73

D/E

0.18

Sector PE

45.33

₹90.38Cr

Peer Comparison

Dividends

What are dividends?

Dividend, in financial terms, means a certain amount shared with shareholders of a company or a mutual fund on a regular basis – monthly, quarterly or annually. Read more

Bonuses

What are bonuses?

A bonus issue is an offer given to the existing shareholders of the company to subscribe for additional shares. Instead of increasing the dividend payout, the companies off... Read more

Company News

Sorry, we do not have any data here.

Sector News

Sorry, we do not have any data here.

About Biocon Ltd

Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company. Some of its key brands are INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab), KRABEVAA (Bevacizumab) and ALZUMAb (Itolizumab), a 'first in class' anti-CD6 monoclonal antibody. The company has a rich pipeline of Biosimilars and Novel Biologics at various stages of development including Insulin Tregopil, a high potential oral insulin. The company's business model spans the entire drug value chain, from pre-clinical discovery to clinical development and through to commercialisation and focused on biopharmaceuticals, custom research and clinical research. Biocon is an ISO 9001, ISO 14001:2004, ISO 9001:2000, ISO 15189:2003 and also OHSAS 18001:1999 certified for various levels. Biocon has two subsidiary companies for support, namely Syngene International Ltd and Clinigene International Ltd. Biocon has rapidly developed a robust drug pipeline, led by monoclonal antibodies and several other molecules at exciting stages in the biopharmaceutical value chain. Biocon Limited was incorporated in the year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw.